✦ LIBER ✦

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

✍ Scribed by A. Craxi; S. Koutsounas; P. Ogurtsov; L. Chemello; M. Maticic; J. Torras; M. Diago; M. T. Tartaglione; T. Witthoeft; X. Yu; R. Faruqi; E. Chaudhri; L. D. Pedicone; E. Zuckerman

Book ID: 108886651
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 265 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2011.01515.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Brian L. Pearlman; Carole Ehleben 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm

A randomized trial of 24 versus 48 weeks

A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan

✍ Yoshiaki Iwasaki; Yasushi Shiratori; Shuhei Hige; Shuhei Nishiguchi; Hitoshi Tak 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 343 KB